Kent DM - Search Results

1

Treating unrelated disorders in patients with chronic disease.

Kent DM, Hayward R. Kent DM, et al. N Engl J Med. 1998 Sep 24;339(13):926; author reply 927-8. doi: 10.1056/NEJM199809243391318. N Engl J Med. 1998. PMID: 9750097 No abstract available.

2

Subgroup analyses in clinical trials.

Kent D, Hayward R. Kent D, et al. N Engl J Med. 2008 Mar 13;358(11):1199; author reply 1199-200. N Engl J Med. 2008. PMID: 18340666 No abstract available.

3

An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.

Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, Selker HP. Kent DM, et al. Am J Med. 2002 Aug 1;113(2):104-11. doi: 10.1016/s0002-9343(02)01160-9. Am J Med. 2002. PMID: 12133748

4

Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus?

Vijan S, Kent DM, Hayward RA. Vijan S, et al. Among authors: kent dm. Diabetologia. 2000 Jan;43(1):125-30. doi: 10.1007/s001250050017. Diabetologia. 2000. PMID: 10672454 Free article. Review.

5

Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

Kent DM, Hayward RA. Kent DM, et al. JAMA. 2007 Sep 12;298(10):1209-12. doi: 10.1001/jama.298.10.1209. JAMA. 2007. PMID: 17848656 No abstract available.

6

Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.

Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP. Kent DM, et al. J Clin Epidemiol. 2004 Aug;57(8):843-52. doi: 10.1016/j.jclinepi.2004.01.008. J Clin Epidemiol. 2004. PMID: 15485737

7

6 EZ steps to improving your performance: (or how to make P4P pay 4U!).

Hayward RA, Kent DM. Hayward RA, et al. Among authors: kent dm. JAMA. 2008 Jul 16;300(3):255-6. doi: 10.1001/jama.2008.69. JAMA. 2008. PMID: 18632535 No abstract available.

8

Treatment Effect Heterogeneity in Clinical Trials: An Evaluation of 13 Large Clinical Trials Using Individual Patient Data.

Kent DM, Nelson J, Altman DG, Hayward RA. Kent DM, et al. Value Health. 2014 Nov;17(7):A543-4. doi: 10.1016/j.jval.2014.08.1756. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201750 Free article. No abstract available.

9

Reporting clinical trial results to inform providers, payers, and consumers.

Hayward RA, Kent DM, Vijan S, Hofer TP. Hayward RA, et al. Among authors: kent dm. Health Aff (Millwood). 2005 Nov-Dec;24(6):1571-81. doi: 10.1377/hlthaff.24.6.1571. Health Aff (Millwood). 2005. PMID: 16284031

10

Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis.

Hayward RA, Kent DM, Vijan S, Hofer TP. Hayward RA, et al. Among authors: kent dm. BMC Med Res Methodol. 2006 Apr 13;6:18. doi: 10.1186/1471-2288-6-18. BMC Med Res Methodol. 2006. PMID: 16613605 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters